Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  VBI Vaccines Inc.    VBIV   CA91822J1030

VBI VACCINES INC.

(VBIV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

VBI Vaccines : signs agreement with Canada to develop COVID-19 vaccine by 2022

share with twitter share with LinkedIn share with facebook
09/21/2020 | 10:36am EDT

VBI Vaccines Inc said on Monday it had entered into an agreement with Canada to develop a potential vaccine for COVID-19 by 2022 through mid-stage trials conducted exclusively in the country.

Canada will contribute around 75% of the U.S.-based company's development costs and C$55.9 million (32.84 million pounds) for the project.

VBI Vaccines said last month that together with the National Research Council Canada it was investigating the vaccine candidate, VBI-2900, in preclinical trials.

As per the agreement, signed last week, the company's Ottawa-based unit is obligated to complete the vaccine development in or before the first quarter of 2022.

There are currently no approved vaccines for COVID-19, but around 38 vaccines are being tested in humans around the world.

(Reporting By Mrinalika Roy in Bengaluru; Editing by Maju Samuel)


Stocks mentioned in the article
ChangeLast1st jan.
NATIONAL RESEARCH CORPORATION -1.30% 52.95 Delayed Quote.-19.70%
VBI VACCINES INC. -3.53% 2.46 Delayed Quote.78.26%
share with twitter share with LinkedIn share with facebook
All news about VBI VACCINES INC.
08:04aVBI VACCINES : Presents Phase 3 Sci-B-Vac® Data at ID Week 2020™
BU
10/15VBI VACCINES : to Present at the H.C. Wainwright Hepatitis B Virus (HBV) Mini-Co..
BU
10/08VBI VACCINES : Announces e-Poster Presentation at The Liver Meeting® 2020
BU
09/24VBI VACCINES : to Present at Upcoming Scientific Conferences
BU
09/21VBI VACCINES : signs agreement with Canada to develop COVID-19 vaccine by 2022
RE
09/17VBI VACCINES : Announces Biomarker Data From VBI-1901 Phase 1/2a Study in Recurr..
BU
09/14VBI VACCINES : to Present Additional Biomarker Data from VBI-1901 Phase 1/2a Stu..
BU
08/31VBI VACCINES : Sci-B-Vac® Phase 3 Data at EASL 2020
PU
08/31VBI VACCINES : Presents Phase 3 Sci-B-Vac® Data at EASL 2020
BU
08/26VBI VACCINES : selects two COVID-19 vaccine candidates for human trials
RE
More news
Financials (USD)
Sales 2020 1,31 M - -
Net income 2020 -38,2 M - -
Net Debt 2020 - - -
P/E ratio 2020 -14,0x
Yield 2020 -
Capitalization 590 M 590 M -
Capi. / Sales 2020 451x
Capi. / Sales 2021 87,8x
Nbr of Employees 124
Free-Float 72,5%
Chart VBI VACCINES INC.
Duration : Period :
VBI Vaccines Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VBI VACCINES INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 6,75 $
Last Close Price 2,55 $
Spread / Highest target 253%
Spread / Average Target 165%
Spread / Lowest Target 17,6%
EPS Revisions
Managers
NameTitle
Jeffrey R. Baxter President, Chief Executive Officer & Director
Steven H. Gillis Chairman
Christopher McNulty CFO, Director & Head-Business Development
David Evander Anderson Chief Scientific Officer
Francisco Diaz-Mitoma Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
VBI VACCINES INC.84.78%590
LONZA GROUP AG62.80%47 152
SEAGEN INC.72.54%34 263
IQVIA HOLDINGS INC.8.39%32 108
CELLTRION, INC.31.49%28 160
MODERNA, INC.260.58%27 830